1
|
Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy.
|
J Clin Oncol
|
2002
|
1.93
|
2
|
EphA2 expression is associated with aggressive features in ovarian carcinoma.
|
Clin Cancer Res
|
2004
|
1.80
|
3
|
The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
|
Am J Surg Pathol
|
2006
|
1.79
|
4
|
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
|
Gynecol Oncol
|
2009
|
1.61
|
5
|
Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer.
|
Clin Cancer Res
|
2005
|
1.39
|
6
|
Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential.
|
Obstet Gynecol
|
2002
|
1.24
|
7
|
Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma.
|
J Clin Microbiol
|
2007
|
1.22
|
8
|
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
|
Gynecol Oncol
|
2008
|
1.19
|
9
|
EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model.
|
Cancer Res
|
2008
|
1.17
|
10
|
Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC).
|
J Transl Med
|
2004
|
1.02
|
11
|
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.
|
Gynecol Oncol
|
2012
|
1.01
|
12
|
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2012
|
0.97
|
13
|
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
|
Clin Cancer Res
|
2003
|
0.96
|
14
|
Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma.
|
Cancer Invest
|
2003
|
0.95
|
15
|
The subcellular localization of syntaxin 17 varies among different cell types and is altered in some malignant cells.
|
J Histochem Cytochem
|
2005
|
0.93
|
16
|
Monocyte/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease.
|
J Transl Med
|
2006
|
0.91
|
17
|
14-3-3 zeta protein secreted by tumor associated monocytes/macrophages from ascites of epithelial ovarian cancer patients.
|
Cancer Immunol Immunother
|
2008
|
0.89
|
18
|
Specific keynote: genome copy number abnormalities in ovarian cancer.
|
Gynecol Oncol
|
2003
|
0.89
|
19
|
A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
|
Gynecol Oncol
|
2004
|
0.87
|
20
|
Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer.
|
Clin Cancer Res
|
2007
|
0.87
|
21
|
Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
|
Arch Pathol Lab Med
|
2015
|
0.76
|
22
|
Subperiostial recurrence of chondroblastoma.
|
Radiol Case Rep
|
2015
|
0.75
|
23
|
Limited utility of magnetic resonance imaging in determining the primary site of disease in patients with inconclusive endometrial biopsy.
|
Int J Gynecol Cancer
|
2010
|
0.75
|
24
|
Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma?
|
Clin Orthop Relat Res
|
2013
|
0.75
|
25
|
The Utility of Core Needle Biopsy and Fine-Needle Aspiration in the Workup of Tumors of Suspected Müllerian Origin.
|
Acta Cytol
|
2016
|
0.75
|
26
|
The natural history of primary temporal bone myxoma.
|
Ann Diagn Pathol
|
2012
|
0.75
|